Roche Sequencing Solutions, Inc.

Roche Diabetes Care, Inc.

Roche Diagnostics Operations, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-La Roche Ag

Thomas Streidl

Victor I Lyamichev

Frank Bergmann

Michael Schraeml

Jigar Patel

Thomas J Albert

Wojtek Steffen

Mara Boenitz-Dulat

Peter Kratzsch

Tobias Oelschlaegel

Daniela Beck

Mohamed Yosry Hassan Mohamed

Carina Horn

Stacy Hunt DuVall

Thomas Albert

Michael Schaeml

Steffen Wojtek

In one aspect, the present disclosure provides a system and method for the identification and characterization of a transglutaminase. Further, the present disclosure provides transglutaminase enzymes for forming isopeptide bonds, methods of forming isopeptide bonds in the presence of transglutaminases, and substrate tags for use with transglutaminases. In another aspect, the present disclosure provides glutamine-containing substrates (or Q-tag substrates) that are more resistant to proteases/clipping and therefore, more stable, than other Q-tag substrates, and their uses in substrate tags for cross-linking to an amine-donor tag via an isopeptide bond mediated by a microbial transglutaminase.

System and method for identification and characterization of transglutaminase species

In one aspect, the present disclosure provides a system and method for the identification and characterization of a transglutaminase. Further, the present disclosure provides transglutaminase enzymes for forming isopeptide bonds, methods of forming isopeptide bonds in the presence of transglutaminases, and substrate tags for use with transglutaminases.

The present invention relates to a mutant 3-hydroxybutyrate dehydrogenase (3-HBDH) with improved performance relative to the wild-type 3-HBDH, a nucleic acid encoding the mutant 3-HBDH, a cell comprising the mutant 3-HBDH or the nucleic acid, a method of determining the amount or concentration of 3-hydroxybutyrate in a sample, and a device for determining the amount or concentration of 3-hydroxybutyrate in a sample.

Mutant 3-hydroxybutyrate dehydrogenase fromas well as methods and uses involving the same

The present disclosure relates to a mutant 3-hydroxybutyrate dehydrogenase (3-HBDH) with improved performance relative to the wild-type 3-HBDH, a nucleic acid encoding the mutant 3-HBDH, a cell having the mutant 3-HBDH or the nucleic acid, and/or a method of determining the amount or concentration of 3-hydroxybutyrate in a sample. Also disclosed is the use of the mutant 3-HBDH for determining the amount or concentration of 3-hydroxybutyrate in a sample, and a device for determining the amount or concentration of 3-hydroxybutyrate in a sample.

Mutant 3-hydroxybutyrate dehydrogenase from alcaligenes faecalis as well as methods and uses involving the same

Growing community of inventors

Seeshaupt, Germany

Thomas Streidl